CDK5 and its activator P35 in normal pituitary and in pituitary adenomas: relationship to VEGF expression.
CDK5 and its activator P35 in normal pituitary and in pituitary adenomas: relationship to VEGF expression.
复制标题
正常垂体和垂体腺瘤中的 CDK5 及其激活剂 P35:与 VEGF 表达的关系
DOI:
10.7150/ijbs.7770
复制
发表时间:
2014
影响因子:
9.2
通讯作者:
Zhang Y
中科院分区:
文献类型:
--
作者:
Xie W;Wang H;He Y;Li D;Gong L;Zhang Y
Pituitary tumors are monoclonal adenomas that account for about 10-15% of intracranial tumors. Cyclin-dependent kinase 5 (CDK5) regulates the activities of various proteins and cellular processes in the nervous system, but its potential roles in pituitary adenomas are poorly understood. The kinase activity of CDK5 requires association with an activating protein, p35 (also known as CDK5 activator 1, p35). Here, we show that functional CDK5, associated with p35, is present in normal human pituitary and in pituitary tumors. Furthermore, p35 mRNA and protein levels were higher in pituitary adenomas than in the normal glands, suggesting that CDK5 activity might be upregulated in pituitary tumors. Inhibition of CDK5 activity in rat pituitary cells, reduced the expression of vascular endothelial growth factor (VEGF), a protein that regulates vasculogenesis and angiogenesis. Our results suggest that increased CDK5-mediated VEGF expression might play a crucial role in the development of pituitary adenomas, and that roscovitine and other CDK5 inhibitors could be useful as anticancer agents.
登录
查看更多内容
影响因子:
9.2
作者:
Gohla, A;Bokoch, GM
通讯作者:
Bokoch, GM
影响因子:
4.8
作者:
Lin, Ho;Chen, Mei-Chih;Lin, Shih-Yi
通讯作者:
Lin, Shih-Yi
影响因子:
3.9
作者:
Shan, B.;Gerez, J.;Renner, U.
通讯作者:
Renner, U.
影响因子:
4.8
作者:
Floyd, SR;Porro, EB;De Camilli, P
通讯作者:
De Camilli, P
DOI:
10.1073/pnas.0712306105
发表时间:
2008-05-27
影响因子:
11.1
作者:
Liu, Ren;Tian, Bo;Mao, Zixu
通讯作者:
Mao, Zixu